查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466528

自行注射藥物市場：按類型、應用、通路、治療領域應用分類 - 全球預測 2024-2030

Self-injections Market by Type (Auto-Injectors, Needle-free Injectors, Pen Injectors), Usage (Disposable, Reusable), Distribution Channel, Therapeutic Areas Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年自行注射藥物市場規模為540億美元，預計2024年將達606.4億美元，2030年將達1,248.7億美元，複合年成長率為12.72%。

自行注射藥物是指在沒有醫療專業人員幫助的情況下，自行透過肌肉注射、皮下注射或靜脈注射給藥的產品。自行注射藥物用於需要定期、長期照護的治療，例如用於治療糖尿病的胰島素、用於荷爾蒙補充療法和不孕症治療的荷爾蒙以及用於慢性疾病的生物製藥。自注射器被廣泛用於增強自主性，並且可以透過消除醫療保健提供者的管理來提高治療依從性。近年來，由於慢性病的增加、家庭保健的需求、藥物輸送技術的進步以及越來越多的患者喜歡自行注射，自行注射毒品的使用率有所增加。然而，研發所需的高額投資、對病人安全和舒適的擔憂以及生技藥品低溫運輸儲存和物流的需求限制了自行注射藥物的產品滲透。數位化和對以患者為中心的認知創造了將智慧技術整合到自行注射設備中的機會。專注於連接的創新可以提供資料收集、病患監測和依從性追蹤，從而實現自行注射藥物的個人化治療方法。此外，政府對自行注射藥物的支持性核准進一步擴大了市場範圍。

主要市場統計
基準年[2023] 540億美元
預測年份 [2024] 606.4億美元
預測年份 [2030] 1248.7億美元
複合年成長率（%） 12.72%

類型 慢性病管理越來越偏好筆型注射器

自動注射器的設計易於使用，讓您只需最少的訓練即可注射精確劑量的藥物。自動注射器用於在緊急情況下輸送救生藥物。需要即時可靠的藥物管理（通常無需醫療保健專業人員的幫助）的患者對自動注射器的需求量很大。無針注射器是傳統注射器注射的替代方案，不需要針頭。無針注射器透過薄薄的高壓注射液穿經皮膚來輸送藥物。有針頭恐懼症的人主要喜歡無針注射器，而需要頻繁注射的人，例如糖尿病患者，可能會經歷針頭疲勞。注射筆廣泛用於慢性疾病的治療，並允許自行注射胰島素和生長激素。筆式注射器可攜帶、隱藏且相對易於使用，這對需要定期給藥同時保持積極生活方式的患者很有吸引力。穿戴式注射器，也稱為貼片幫浦，是一種緊密貼合患者身體的裝置，可在較長時間內提供連續或受控的藥物輸送。穿戴式注射器主要用於需要長期治療的患者。自動注射器和筆式注射器因其易用性和可靠性而通常受到青睞。另一方面，無針和穿戴式注射器適合尋求侵入性較小或更靈活的藥物輸送方法的患者。

用途：越來越多使用一次性自行注射，以避免交叉污染的風險。

拋棄式自動注射器是一次性注射器，因其方便、安全和降低交叉污染的風險而受到青睞。需要短期藥物治療或優先考慮低注射器維護的患者通常選擇一次性自動注射器。對於感染疾病風險高的疾病，首選一次性注射器。可重複使用的自動注射器是多用途系統，是需要長期用藥的慢性病患者的首選。可重複使用的自動注射器具有成本效益，需要定期維護，並且經久耐用。可重複使用的注射器是長期給藥方案的首選。一次性注射器方便又安全，特別是對於不需要長期用藥的患者。

分銷管道：自行注射藥品新滲透線上平台

醫院藥屋主要為與醫療機構直接相連的住院患者和門診病人提供服務。在住院期間接受自行注射治療的患者通常會直接從醫院藥房獲得最初的自行注射設備。需要自行注射設備使用專門指導的患者以及尋求額外支持和指導的患者更喜歡醫院藥房。電子商務的興起延伸到了製藥業，網路藥局提供便利、謹慎和低廉的價格。網路藥局特別適合已經習慣自行注射方案、喜歡宅配的患者。優先考慮便利性、行動不便或行動不便且有穩定的自行注射方案的患者更有可能選擇網路藥局。私人診所提供個人化護理，並為希望與值得信賴的醫療保健提供者保持連續性的患者提供服務。私人診所有利於接受自行注射治療，這需要醫療保健專業人員的持續監測和追蹤。醫院藥房因其方便的訪問和患者教育資源而受到青睞，在線藥房因其便利和潛在的成本節省而受到青睞，而私人診所則因其個性化的持續護理而受到青睞。

治療應用：擴大自行注射藥物在荷爾蒙問題治療的使用

自行注射療法對於治療自體免疫疾病（包括類風濕性關節炎和紅斑性狼瘡）至關重要。生物製藥，包括Adalimumab和Etanercept，透過自行注射來管理發炎和改變疾病進展。在愛滋病的治療中，自行注射抗逆轉錄病毒藥物製劑有可能透過提供較低頻率的給藥選擇來提高依從性。自行注射腎上腺素自動注射器是嚴重過敏患者的救命設備。自行注射藥物可以在發生過敏反應時立即進行治療，以防止潛在的致命性過敏反應。對於腫瘤患者來說，自行注射藥物如顆粒細胞增生因子（G-CSF）可以幫助控制化療引起的嗜中性白血球低下症。自行注射減少了頻繁就診的需要，並支持癌症治療的連續性。自行注射療法治療包括克隆氏症在內的腸躁症，使用發炎和免疫抑制藥物，對於控制症狀和誘導長期緩解至關重要。含有BETA干擾素的自行注射藥物是多發性硬化症患者治療方法的主要支柱，有助於控制症狀並減緩疾病進展。

在乾癬中，自行注射生物製藥針對免疫系統內的特定途徑來抑制過度的發炎反應。自行注射緊急藥物旨在發生危機時快速給藥，例如腎上腺素、升糖素和納洛酮自動注射器，用於治療急性過敏反應、嚴重低血糖和藥物過量攝取。腎上腺素注射器是過敏性休克（嚴重且可能危及生命的過敏反應）期間的第一道防線。自行注射偏頭痛治療可快速緩解偏頭痛症狀。自行注射藥物比內服藥物更快地阻止偏頭痛發作，這對症狀嚴重或出現噁心和嘔吐的患者有益。荷爾蒙補充療法中使用的自行注射藥物可以提供穩定劑量的睪固酮、雌激素和黃體酮等激素，這對荷爾蒙缺乏症患者和跨性別患者有益。 BETA干擾素自行注射主要用於治療多發性硬化症、減少發炎並降低復發頻率。促紅血球生成素（EPO）自行注射對於治療慢性腎臟病病患者的貧血至關重要。促紅血球生成素 (EPO)自行注射可刺激紅血球生成，有助於減少輸血需求。濾泡刺激素（FSH）自行注射在不孕症治療中發揮重要作用。它刺激女性卵巢的生長和男性精子發生。低分子肝素自行注射為長期門診抗凝血提供了一個易於使用的選擇，通常用於血栓症形成風險的患者的抗凝血。自行注射胰島素是糖尿病管理的基本治療方法，由於可以根據血糖值和飲食攝取量來注射胰島素，因此具有彈性並能提供良好的血糖控制。對於骨質疏鬆症患者，自行注射副甲狀腺素可以透過刺激新骨生長來幫助提高骨骼密度，這對於治療嚴重骨質疏鬆症至關重要。帕金森氏症患者可以從自行注射藥物中受益，這些藥物可以緩解症狀並減緩疾病的進展。

區域洞察

美洲的自行注射藥物市場受到以患者為中心的護理、先進的醫療基礎設施以及需要患者友好型管理的生物製藥的日益核准的推動。消費者越來越意識到自我護理的選擇，包括方便的自我注射器。政府為縮短住院時間和促進自我注射藥物所做的努力也促進了美洲自行注射藥物的普及。在歐盟（EU），人口老化、慢性病盛行率上升以及對自我管理的日益偏好正在支持自動注射器市場的成長。歐盟嚴格的法律規範確保了自行注射裝置的高安全標準。此外，一些歐盟國家正在積極實施病患教育計劃，以促進自行注射的採用。在中東和非洲，醫療基礎設施的大規模投資以及與文明病的增加表明自動注射器市場的成長前景良好。在亞太地區，快速的經濟成長和不斷成長的醫療保健支出是自行注射藥品市場的主要促進因素。政府對藥物創新的重視和慢性病的激增正在推動需求。此外，技術先進的醫療保健系統和人口老化正在支持亞太地區的自動注射器市場。

FPNV定位矩陣

FPNV定位矩陣對於評估自行注射藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對自行注射藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.自行注射藥品市場規模及預測如何？

2.自行注射藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.自行注射藥品市場的技術趨勢和法規結構是什麼？

4.自行注射藥品市場主要廠商的市場佔有率是多少？

5. 進入自行注射藥品市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性疾病和類風濕性關節炎的快速傳播
      • 用於不孕症治療的自行注射藥物的廣泛使用
    • 抑制因素
      • 產品召回的潛在風險
    • 機會
      • 世界各地政府正在核准自行注射
      • 自動注射器的技術進步
    • 任務
      • 與自行注射藥物相關的認知有限和管理挑戰
  • 市場區隔分析
    • 類型：在慢性病管理中越來越偏好筆式注射器
    • 用途：一次性自行注射的使用越來越多，以避免交叉污染的風險
    • 通路：自行注射毒品在網路平台的普及
    • 治療領域的應用：自行注射藥物治療荷爾蒙問題的應用正在擴大
  • 市場趨勢分析
    • 糖尿病和慢性病的增加正在增加美洲對自行注射藥物的需求
    • 增加對亞太地區醫療保健基礎設施和自行注射藥物器材創新的投資
    • 歐洲、中東和非洲地區政府支持核准自行注射藥物
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章自行注射藥品市場：依類型

  • 自動注射器
  • 無針注射器
  • 筆式注射器
  • 穿戴式注射器

第7章自行注射藥品市場應用

  • 一次性的
  • 可重複使用的

第8章自行注射藥品市場：依通路

  • 醫院藥房
  • 網路藥房
  • 私人診所

第9章依治療領域自行注射藥品市場應用

  • 自體免疫疾病
  • 急救藥品
  • 荷爾蒙補充療法

第10章 美洲自行注射藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太自行注射藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲/中東/非洲自行注射藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • 美光生物醫學公司獲得資金生產無針疫苗
    • Enable Injections 首次獲得美國食品藥物管理局(FDA)核准
    • Altaviz 推出新型藥物輸送自動注射器平台
    • FDA核准用於 PNH 治療的自用內置注射器 pegcetacoplan
    • Civica 與 Ipsomed 合作開發胰島素注射筆
    • Eitan Medical完成穿戴式注射器業務轉型
    • Coherus 宣佈在美國推出 UDENYCA 自動注射器
    • Ypsomed 透過綜合人因服務增強自行注射設備平台
    • Viridian Therapeutics 宣布與藥物傳輸創新者 Enable Injections 合作
    • 美國FDA核准Tezspire 使用預填充筆進行自我給藥
    • Philips Medisize 推出筆式注射器平台，擴大產品系列，旨在降低藥品成本、風險和市場壁壘

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-03050D1B2DB4

[195 Pages Report] The Self-injections Market size was estimated at USD 54.00 billion in 2023 and expected to reach USD 60.64 billion in 2024, at a CAGR 12.72% to reach USD 124.87 billion by 2030.

Self-injections refer to the products used to administer medication to themselves intramuscularly, subcutaneously, or intravenously without the immediate assistance of healthcare professionals. Self-injections are used for treatments that require regular and long-term care, such as insulin for diabetes, hormones for hormone replacement therapy and fertility treatments, and biologics for chronic conditions. Self-injection devices are widely used to increase autonomy and can improve treatment adherence by eliminating the need for healthcare provider administration. An elevating prevalence of chronic diseases, the need for home-based healthcare, advancements in drug delivery technology, and a growing patient preference for self-administration have improved the usage of self-injections in recent years. However, the requirement for significant investment in research and development, patient safety and comfort concerns, and the need for cold chain storage and logistics for biologics limit the product penetration of self-injections. Recognition of digitization and patient-centricity leads to opportunities for integrating smart technology into self-injection devices. Innovations focusing on connectivity can provide data collection, patient monitoring, and adherence tracking, guiding personalized treatment modalities for self-injections. Moreover, the supportive government approvals for self-injections are further expanding the scope of the market.

KEY MARKET STATISTICS
Base Year [2023] USD 54.00 billion
Estimated Year [2024] USD 60.64 billion
Forecast Year [2030] USD 124.87 billion
CAGR (%) 12.72%

Type: Rising preference for pen injectors to manage chronic diseases

Auto-injectors are designed for convenient use and can administer a precise dose of medication with minimal training. Auto-injectors are used for the delivery of life-saving drugs in emergencies. The need-based preference for auto-injectors is high among patients who require immediate and reliable administration of drugs, often without the assistance of healthcare professionals. Needle-free injectors offer an alternative to traditional syringe injections, removing the need for needles. Needle-free injectors use a high-pressure, narrow jet of the injection liquid to penetrate the skin to deliver the medication. Individuals with needle phobia mainly prefer needle-free injectors or those who require frequent injections, such as diabetic patients who may otherwise experience needle fatigue. Pen injectors are widely used to manage chronic diseases, allowing insulin or growth hormone self-administration. Pen injectors are portable, discreet, and relatively easy to use, appealing to patients who need to administer medication regularly while maintaining an active lifestyle. Wearable injectors, also known as patch pumps, are devices that adhere to the patient's body and provide continuous or controlled delivery of drugs over an extended period. Wearable injectors are primarily used by patients who require long-term therapies. Auto-injectors and pen injectors are generally favored for their ease of use and reliability. In contrast, needle-free and wearable injectors cater to patients seeking a less invasive or more flexible approach to medication delivery.

Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination

Disposable self-injection devices are single-use injectors preferred for their convenience, safety, and the reduced risk of cross-contamination. Disposable self-injection devices are often chosen by patients requiring short-term medication regimens or those prioritizing the ease of not having to manage the maintenance of the device. Disposable injectors are preferred for diseases with a high risk of infection transmission. Reusable self-injection devices are multi-use systems that offer cost benefits over time and are favored by patients with chronic conditions requiring long-term medication delivery. Reusable self-injection devices are cost-effective, necessitate regular maintenance and are designed for durable use. Reusable injectors are preferred for long-term medication regimens. Disposable injectors offer convenience and safety, especially for patients not requiring long-term medication.

Distribution Channel: Emerging penetration of self-injections on online platforms

Hospital pharmacies primarily serve inpatients and outpatients directly connected to medical facilities. Patients who have been prescribed self-injection therapies during a hospital stay often receive their initial supply of self-injection equipment directly from the hospital pharmacy. Patients requiring specialized instruction on the use of self-injection devices or seeking high-touch support and guidance prefer hospital pharmacies. The rise of eCommerce has extended to the pharmaceutical field, with online pharmacies offering convenience, discretion, and lower prices. Online pharmacies are particularly well-suited for those who are already familiar with their self-injection regimen and prefer home delivery. Patients who prioritize convenience, have mobility and transportation challenges or have a stable self-injection regime choose online pharmacies highly. Private clinics offer personalized care and cater to patients looking for a certain continuity of care with a healthcare provider they trust. Private clinics can be beneficial for receiving self-injection therapies that require consistent monitoring and follow-up with the healthcare practitioner. Hospital pharmacies are preferred for their immediate accessibility and patient education resources, online pharmacies for convenience and potential cost savings, and private clinics for personalized, ongoing care.

Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues

Self-injection therapies are pivotal for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. Biological agents, including adalimumab and etanercept, are administered via self-injection to manage inflammation and modify disease progression. In the management of AIDS, self-injectable formulations of antiretroviral drugs may enhance adherence by providing less frequent dosing options. Self-injectable epinephrine auto-injectors are life-saving devices for individuals with severe allergies. Self-injections allow for immediate treatment in the case of an allergic reaction, preventing potentially fatal anaphylaxis. For oncology patients, self-injectables such as granulocyte colony-stimulating factors (G-CSF) help manage chemotherapy-induced neutropenia. Self-administration can mitigate the need for frequent healthcare visits and support the continuity of cancer treatment. Self-injectable therapies in the treatment of irritable bowel disorders, including Crohn's disease, involve anti-inflammatory and immunosuppressive drugs, which are vital in controlling symptoms and inducing long-term remission. Self-administered injectable medications, including beta-interferon, are a mainstay in the treatment regimen for multiple sclerosis patients to assist in managing symptoms and slow the progression of the disorder.

In psoriasis, self-injectable biologics target specific pathways within the immune system to reduce the overactive inflammatory response. Self-injectable emergency drugs, designed for rapid administration in crises, include treatments for acute allergic reactions, severe hypoglycemia, and narcotic overdoses, exemplified by epinephrine, glucagon, and naloxone auto-injectors, respectively. Epinephrine auto-injectors are the first line of defense during anaphylactic shocks, a severe, potentially life-threatening allergic reaction. Self-injectable treatments for migraines offer rapid relief of migraine symptoms. Self-injections can abort migraine attacks more quickly than oral medications, which is beneficial for patients with severe symptoms or those experiencing nausea and vomiting. Self-injectables used in hormone replacement therapies provide a consistent delivery method for hormones, including testosterone, estrogen, or progesterone, benefiting patients with hormonal deficiencies or in transgender care. Beta-interferon self-injections are used primarily to treat multiple sclerosis, reduce inflammation, and decrease the frequency of relapse episodes. Erythropoietin (EPO) self-injectables are essential for patients with chronic kidney disease to combat anemia. Erythropoietin (EPO) self-injectables stimulate red blood cell production and help to reduce the need for blood transfusions. Self-injectable follicle-stimulating hormone (FSH) plays a crucial role in fertility treatments. It stimulates ovary follicle growth in women and spermatogenesis in men. Low molecular weight heparin self-injections are commonly used for anticoagulation in patients at risk for thrombosis to provide an easy-to-use option for long-term outpatient anticoagulation therapy. Self-injected insulin is a cornerstone treatment for diabetes management that allows individuals to dose insulin according to their blood glucose levels and dietary intake, providing flexibility and better glycemic control. For osteoporosis patients, self-injected parathyroid hormone can help improve bone density by stimulating new bone growth, an essential aspect of managing severe osteoporosis. Parkinson's disease patients may benefit from self-injectable medications that can provide symptomatic relief or slow disease progression.

Regional Insights

The self-injections market in the Americas is driven by a strong emphasis on patient-centric care, advanced healthcare infrastructure, and an increase in biologic drug approvals that require patient-friendly administration. Consumers are becoming increasingly aware of self-care options, including self-injection devices, which align with convenience. Government initiatives to reduce hospital stays and promote self-administration of medication also contribute to the penetration of self-injections in the Americas. In the European Union, market growth for self-injection devices is supported by an aging population, the prevalence of chronic diseases, and a strong inclination toward self-management of these conditions. The EU's rigorous regulatory framework ensures high safety standards for self-injection devices. Furthermore, several EU countries have been active in running patient education programs to encourage the adoption of self-injection practices. In the Middle East and Africa, substantial investments in healthcare infrastructure and an increasing incidence of lifestyle-related diseases show promising growth for the self-injections market. In the Asia-Pacific region, rapid economic growth and increased healthcare expenditure are major drivers for the self-injections market. The government's emphasis on pharmaceutical innovation and the surging prevalence of chronic diseases are boosting demand. Furthermore, a technologically advanced healthcare system and an aging population enable the market for self-injection devices in the Asia Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Self-injections Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Self-injections Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Self-injections Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Antares Pharma, Inc. by Halozyme, Inc., AstraZeneca plc, Baxter International, Inc., Becton, Dickinson and Company, Credence MedSystems, Inc., DALI Medical Devices Ltd., Eli Lilly and Company, Enable Injections, Inc., Gerresheimer AG, GlaxoSmithKline plc, Insulet Corporation, Johnson & Johnson Services, Inc., Medmix AG by Sulzer Ltd., Merck KGaA, Molex LLC by Koch Industries, Inc., Mylan N.V. by Viatris Inc., Novo Nordisk A/S, Owen Mumford Limited, PenJet Corporation, Pfizer Inc., PharmaJet, Inc., Recipharm AB, Sanofi S.A., SCHOTT AG, SHL Medical AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., West Pharmaceutical Services, Inc., and Ypsomed Group.

Market Segmentation & Coverage

This research report categorizes the Self-injections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Auto-Injectors
    • Needle-free Injectors
    • Pen Injectors
    • Wearable Injectors
  • Usage
    • Disposable
    • Reusable
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Private Clinics
  • Therapeutic Areas Application
    • Autoimmune Diseases
      • AIDS
      • Allergies
      • Cancer
      • Irritable Bowel Disorders
      • Multiple Sclerosis
      • Psoriasis
    • Emergency Drugs
      • Anaphylactic Socks
      • Migraine
    • Hormone Replacement Therapies
      • Beta-Interferon
      • Erythropoietin
      • Follicle Stimulating Hormone
      • Heparin
      • Insulin
      • Parathyroid Hormone
      • Parkinson's
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Self-injections Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Self-injections Market?

3. What are the technology trends and regulatory frameworks in the Self-injections Market?

4. What is the market share of the leading vendors in the Self-injections Market?

5. Which modes and strategic moves are suitable for entering the Self-injections Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid prevalence of chronic diseases and rheumatoid arthritis
      • 5.1.1.2. Wide availability of self-injections for fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing government approvals for self-injections worldwide
      • 5.1.3.2. Technological advancements in self-injection devices
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and administration challenges associated with self-injections
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising preference for pen injectors to manage chronic diseases
    • 5.2.2. Usage: Growing use of disposable self-injections to avoid the risk of cross-contamination
    • 5.2.3. Distribution Channel: Emerging penetration of self-injections on online platforms
    • 5.2.4. Therapeutic Areas Application: Growing applications of self-injections to treat hormonal issues
  • 5.3. Market Trend Analysis
    • 5.3.1. Rising incidents of diabetes and chronic diseases creating need for self-injections in the Americas
    • 5.3.2. Growing investment in healthcare infrastructure and innovation in self-injections devices in APAC region
    • 5.3.3. Supportive government approvals for self-injections in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Self-injections Market, by Type

  • 6.1. Introduction
  • 6.2. Auto-Injectors
  • 6.3. Needle-free Injectors
  • 6.4. Pen Injectors
  • 6.5. Wearable Injectors

7. Self-injections Market, by Usage

  • 7.1. Introduction
  • 7.2. Disposable
  • 7.3. Reusable

8. Self-injections Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Private Clinics

9. Self-injections Market, by Therapeutic Areas Application

  • 9.1. Introduction
  • 9.2. Autoimmune Diseases
  • 9.3. Emergency Drugs
  • 9.4. Hormone Replacement Therapies

10. Americas Self-injections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Self-injections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Self-injections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Micron Biomedical Receives Funds To Produce Needle-Free Vaccines
    • 13.3.2. Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
    • 13.3.3. Altaviz introduces New Auto-Injector Platform For Drug Delivery
    • 13.3.4. FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH
    • 13.3.5. Civica Partners With Ypsomed For Insulin Injection Pen
    • 13.3.6. Eitan Medical Completes Transition of Wearable Injectors Business
    • 13.3.7. Coherus Announces U.S. Launch of UDENYCA Autoinjector
    • 13.3.8. Ypsomed Enhances Self-Injection Device Platforms With Integrated Human Factors Services
    • 13.3.9. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
    • 13.3.10. US FDA Approves Tezspire For Self-Administration Using Pre-Filled Pen
    • 13.3.11. Phillips-Medisize Expands Product Portfolio with Launch of a Pen Injector Platform Designed to Lower Pharma Costs, Risks and Market Barriers

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SELF-INJECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. SELF-INJECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SELF-INJECTIONS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SELF-INJECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. SELF-INJECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SELF-INJECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SELF-INJECTIONS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SELF-INJECTIONS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SELF-INJECTIONS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PEN INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SELF-INJECTIONS MARKET SIZE, BY WEARABLE INJECTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISPOSABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SELF-INJECTIONS MARKET SIZE, BY REUSABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SELF-INJECTIONS MARKET SIZE, BY AIDS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ALLERGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL SELF-INJECTIONS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL SELF-INJECTIONS MARKET SIZE, BY IRRITABLE BOWEL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PSORIASIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ANAPHYLACTIC SOCKS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL SELF-INJECTIONS MARKET SIZE, BY MIGRAINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL SELF-INJECTIONS MARKET SIZE, BY BETA-INTERFERON, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL SELF-INJECTIONS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL SELF-INJECTIONS MARKET SIZE, BY FOLLICLE STIMULATING HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL SELF-INJECTIONS MARKET SIZE, BY HEPARIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL SELF-INJECTIONS MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 72. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARATHYROID HORMONE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 73. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 74. GLOBAL SELF-INJECTIONS MARKET SIZE, BY PARKINSON'S, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 122. CANADA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 123. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 124. CANADA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 133. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. MEXICO SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 136. MEXICO SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 137. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. MEXICO SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MEXICO SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 142. MEXICO SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 150. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 151. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 152. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 153. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 156. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 157. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 158. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 159. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 160. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES SELF-INJECTIONS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SELF-INJECTIONS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 182. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 184. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 188. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 190. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 192. AUSTRALIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 193. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. CHINA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 196. CHINA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 197. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. CHINA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. CHINA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 202. CHINA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 203. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 204. CHINA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 205. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 206. CHINA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 207. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 210. INDIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 211. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. INDIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. INDIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 216. INDIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 217. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 218. INDIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 219. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 220. INDIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 221. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. INDONESIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 224. INDONESIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 225. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. INDONESIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. INDONESIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 230. INDONESIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 231. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 232. INDONESIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 233. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 234. INDONESIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 235. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. JAPAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 238. JAPAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 239. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. JAPAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. JAPAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 244. JAPAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 245. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. JAPAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 248. JAPAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 249. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 252. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 253. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 258. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 259. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 260. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 261. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 262. MALAYSIA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 266. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 272. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 274. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 276. PHILIPPINES SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 277. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 280. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 281. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 282. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 283. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 284. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 285. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 286. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 287. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 288. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 289. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 290. SINGAPORE SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 294. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 300. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 301. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 302. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 303. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 304. SOUTH KOREA SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 305. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. TAIWAN SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 308. TAIWAN SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 309. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 310. TAIWAN SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 311. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. TAIWAN SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 314. TAIWAN SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 315. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 316. TAIWAN SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 317. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 318. TAIWAN SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 319. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. THAILAND SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 322. THAILAND SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 323. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 324. THAILAND SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 325. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. THAILAND SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 328. THAILAND SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 329. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 330. THAILAND SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 331. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2018-2023 (USD MILLION)
  • TABLE 332. THAILAND SELF-INJECTIONS MARKET SIZE, BY HORMONE REPLACEMENT THERAPIES, 2024-2030 (USD MILLION)
  • TABLE 333. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. VIETNAM SELF-INJECTIONS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2018-2023 (USD MILLION)
  • TABLE 336. VIETNAM SELF-INJECTIONS MARKET SIZE, BY USAGE, 2024-2030 (USD MILLION)
  • TABLE 337. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 338. VIETNAM SELF-INJECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 339. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. VIETNAM SELF-INJECTIONS MARKET SIZE, BY THERAPEUTIC AREAS APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2023 (USD MILLION)
  • TABLE 342. VIETNAM SELF-INJECTIONS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2024-2030 (USD MILLION)
  • TABLE 343. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 344. VIETNAM SELF-INJECTIONS MARKET SIZE, BY EMERGENCY DRUGS, 2024-203